BioCardia
BCDA
22 hedge funds and large institutions have $9.01M invested in BioCardia in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 4 closing their positions.
230% more call options, than puts
Call options by funds: $228K | Put options by funds: $69K
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
10% more funds holding
Funds holding: 20 → 22 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.1% less ownership
Funds ownership: 1.23% → 1.13% (-0.1%)
27% less capital invested
Capital invested by funds: $12.3M → $9.01M (-$3.29M)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Family Management
New York
|
+$465K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$143K |
| 3 |
State Street
Boston,
Massachusetts
|
+$68.6K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$53.9K |
| 5 |
Millennium Management
New York
|
+$32.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$1.04M |
| 2 |
Renaissance Technologies
New York
|
-$192K |
| 3 |
VF
Virtu Financial
New York
|
-$132K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$86K |
| 5 |
MFG
Magnus Financial Group
New York
|
-$60K |
BCDA Hedge Fund Activity: Q3 2021 in Review
22 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in BioCardia (BCDA) for Q3 2021, worth a combined $9.01M — down 27% from $12.3M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BCDA positions and 4 closed out — a net gain of 2 holders — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Family Management, opening a new position worth an estimated $465K. The largest seller was Roumell Asset Management, cutting an estimated $1.04M.
- 22 institutional investors held BioCardia (BCDA) as of Q3 2021, up from 20 in Q2 2021.
- Funds reported $9.01M of BioCardia stock for Q3 2021, down 27% quarter-over-quarter.
- 6 funds opened new BioCardia positions in Q3 2021 and 4 closed out, a net change of +2 holders.
- The largest BioCardia buyer in Q3 2021 was Family Management, an estimated $465K added.
- The largest BioCardia seller in Q3 2021 was Roumell Asset Management, an estimated $1.04M sold.
Based on aggregated 13F filings for Q3 2021.